Global Novel Drug Delivery Systems Market By Carrier Type (Liposomes, Phytosomes, Nanoparticles, Niosomes, Proniosomes, Microspheres, Emulsions, Ethosomes, Transfereosomes, Others); By Route Of Administration(Oral, Inhalation, Skin Absorption, Intravenous, Pulmonary Route, Others); By End-Users (Research Institutions, Healthcare Facilities, Speciality Clinics, Pharmaceutical Companies, Geriatric Care Centres, Others); By Type (Targeted Drug Delivery, Controlled Drug Delivery, Modulated Drug Delivery); By Application(Humans, Animals); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Drug delivery research has gained immense attention in the last two decades. Researchers are increasingly developing novel drug delivery systems that help in enhancing the absorption of drugs in the body, and reduce wastage. These delivery systems also reduces the pain associated with certain modes of drug delivery. The rising demand for optimizing drug delivery, in both animals and humans, coupled with the advancement in medical technology that combines software programming with drug delivery, is paving way for the growth of the global novel drug delivery systems market.
COVID-19 Impact:
The spread of the Coronavirus in 2020 has resulted in serious disruption of businesses, and has also resulted in the increased load in the healthcare and pharmaceutical sector. The virus has claimed over five million lives so far, and rapid mutations in the virus is causing worry amongst healthcare professionals and government bodies. The rolling out of the vaccines has reduced the severity of COVID-19 infections, but the numbers are still on the rise due to mutations. Due to this, numerous countries have been forced to implement lockdown and social distancing norms to ensure the sound health of individuals. However, the pandemic has created additional growth opportunities for the global novel drug delivery systems market, as researchers are increasingly looking at methods to increase the effectiveness of the COVID-19 vaccine, along with ensuring proper delivery of medicines to the affected patients. There has also been ample focus on other fields of medicine, especially cancer research, and companies are increasingly trying to counter the effects of cancer medicine using targeted drug delivery. Rise in funding in the healthcare and pharmaceutical sector, by both private and public entities, is facilitating the growth of the global novel drug delivery systems market. Therefore, the pandemic has certainly impacted the global novel drug delivery systems market growth.
In terms of revenue, the global novel drug delivery systems market is anticipated to grow at a CAGR of 8.12% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Novel Drug Delivery Systems Market Revenue & Forecast, (US$ Million), 2021 – 2029
Application Outlook:
Humans accounted for the higher revenue share in the global novel drug delivery systems market in 2020. The greater investment in improving drug delivery for humans, especially from government bodies, coupled with the higher instances of deadly diseases such as cancer and brain tumour amongst humans is paving way for the growth of novel drug delivery systems for human-based applications. Insulin delivery, for instance, is gaining traction off late. Studies show that around 8.3 million people in the U.S. require external insulin supply to maintain their blood glucose levels. Furthermore, the global intake of insulin is estimated to rise by 20 percent by 2030. Hence, optimal delivery of insulin can help in the proper intake of insulin, thereby reducing wastage and increasing absorption. Insulet, for instance, provides a system called OmniPod Delivery System which aims at the delivery of insulin using tubeless methods. The OmniPod helps in direct delivery of insulin, and it is programmable in nature. The market participants are increasingly coming up with drug delivery systems aimed at the geriatric and child population.
Region Outlook:
North America accounted for the highest market share in the global novel drug delivery systems market, as far as the regional revenue in 2020 is concerned. The presence of prominent drug delivery system providers such as Abbot, Johnson & Johnson, BD, etc., coupled with the rise in investment in targeted drug delivery related research in Canada and the U.S. contributed heavily towards the higher share of North America in the global novel drug delivery systems market. Furthermore, the spending on healthcare is also on the higher side in the U.S., which in turn helps in facilitating advancement in drug delivery, as individuals are keen on availing medical services that are efficient and sustainable. These factors are helping North America generate the highest revenue in the global novel drug delivery systems market.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global novel drug delivery systems market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global novel drug delivery systems market are:
- Abbott
- Bayer AG
- Becton, Dickinson and Company
- BoehringerIngelheim International GmbH
- Enable Injections
- GlaxoSmithKline plc.
- Insulet Corporation
- Johnson & Johnson Services, Inc.
- KINDEVA DRUG DELIVERY
- Koninklijke Philips N.V.
- Lonza Group Ltd.
- Merck KGaA
- Nemera
- Novartis International AG
- Rapid Dose Therapeutics Inc.
- West Pharmaceutical Services, Inc.
- Other Market Participants
Global Novel Drug Delivery Systems Market
By Carrier Type
- Liposomes
- Phytosomes
- Nanoparticles
- Niosomes
- Proniosomes
- Microspheres
- Emulsions
- Ethosomes
- Transfereosomes
- Others
By Route of Administration
- Oral
- Inhalation
- Skin Absorption
- Intravenous
- Pulmonary Route
- Others
By Type
- Targeted Drug Delivery
- Controlled Drug Delivery
- Modulated Drug Delivery
By Application
- Humans
- Animals
By End-Users
- Research Institutions
- Healthcare Facilities
- Speciality Clinics
- Pharmaceutical Companies
- Geriatric Care Centres
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Novel Drug Delivery Systems Market
6.
Market
Synopsis: Novel Drug Delivery Systems
Market
7.
Novel
Drug Delivery Systems Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Novel Drug Delivery Systems Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Novel Drug Delivery Systems Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Novel Drug Delivery
Systems Market
8.
Global
Novel Drug Delivery Systems Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn)
8.2. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Carrier Type
8.2.1. Liposomes
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Phytosomes
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Nanoparticles
8.2.3.1.
Definition
8.2.3.2.
Market Estimation
and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Niosomes
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Proniosomes
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.5.3.
Market
Forecast, 2021 - 2029
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.2.6. Microspheres
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.6.3.
Market
Forecast, 2021 - 2029
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 - 2020
8.2.6.5.1.2. Market Forecast, 2021 - 2029
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2020
8.2.6.5.2.2. Market Forecast, 2021 - 2029
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2020
8.2.6.5.3.2. Market Forecast, 2021 - 2029
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2020
8.2.6.5.4.2. Market Forecast, 2021 - 2029
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 - 2020
8.2.6.5.5.2. Market Forecast, 2021 - 2029
8.2.7. Emulsions
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.7.3.
Market
Forecast, 2021 - 2029
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 - 2020
8.2.7.5.1.2. Market Forecast, 2021 - 2029
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2020
8.2.7.5.2.2. Market Forecast, 2021 - 2029
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2020
8.2.7.5.3.2. Market Forecast, 2021 - 2029
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2020
8.2.7.5.4.2. Market Forecast, 2021 - 2029
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 - 2020
8.2.7.5.5.2. Market Forecast, 2021 - 2029
8.2.8. Ethosomes
8.2.8.1.
Definition
8.2.8.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.8.3.
Market
Forecast, 2021 - 2029
8.2.8.4.
Compound
Annual Growth Rate (CAGR)
8.2.8.5.
Regional
Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 - 2020
8.2.8.5.1.2. Market Forecast, 2021 - 2029
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 - 2020
8.2.8.5.2.2. Market Forecast, 2021 - 2029
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 - 2020
8.2.8.5.3.2. Market Forecast, 2021 - 2029
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 - 2020
8.2.8.5.4.2. Market Forecast, 2021 - 2029
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 - 2020
8.2.8.5.5.2. Market Forecast, 2021 - 2029
8.2.9. Transfereosomes
8.2.9.1.
Definition
8.2.9.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.9.3.
Market
Forecast, 2021 - 2029
8.2.9.4.
Compound
Annual Growth Rate (CAGR)
8.2.9.5.
Regional
Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 - 2020
8.2.9.5.1.2. Market Forecast, 2021 - 2029
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 - 2020
8.2.9.5.2.2. Market Forecast, 2021 - 2029
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 - 2020
8.2.9.5.3.2. Market Forecast, 2021 - 2029
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 - 2020
8.2.9.5.4.2. Market Forecast, 2021 - 2029
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 - 2020
8.2.9.5.5.2. Market Forecast, 2021 - 2029
8.2.10. Others
8.2.10.1.
Definition
8.2.10.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.10.3.
Market
Forecast, 2021 - 2029
8.2.10.4.
Compound
Annual Growth Rate (CAGR)
8.2.10.5.
Regional
Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 - 2020
8.2.10.5.1.2. Market Forecast, 2021 - 2029
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 - 2020
8.2.10.5.2.2. Market Forecast, 2021 - 2029
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 - 2020
8.2.10.5.3.2. Market Forecast, 2021 - 2029
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 - 2020
8.2.10.5.4.2. Market Forecast, 2021 - 2029
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 - 2020
8.2.10.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Carrier Type
9.
Global
Novel Drug Delivery Systems Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
9.2.1. Oral
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Inhalation
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Skin Absorption
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4. Intravenous
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.2.5. Pulmonary Route
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.5.3.
Market
Forecast, 2021 - 2029
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2015 - 2020
9.2.5.5.1.2. Market Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2020
9.2.5.5.2.2. Market Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2020
9.2.5.5.3.2. Market Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2020
9.2.5.5.4.2. Market Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2015 - 2020
9.2.5.5.5.2. Market Forecast, 2021 - 2029
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.6.3.
Market
Forecast, 2021 - 2029
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market Estimation, 2015 - 2020
9.2.6.5.1.2. Market Forecast, 2021 - 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2020
9.2.6.5.2.2. Market Forecast, 2021 - 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2020
9.2.6.5.3.2. Market Forecast, 2021 - 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2020
9.2.6.5.4.2. Market Forecast, 2021 - 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market Estimation, 2015 - 2020
9.2.6.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global Novel Drug Delivery Systems Market
Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Type
10.2.1. Targeted Drug Delivery
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.1.3.
Market
Forecast, 2021 - 2029
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Controlled Drug Delivery
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.2.3.
Market
Forecast, 2021 - 2029
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Modulated Drug Delivery
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.3.3.
Market
Forecast, 2021 - 2029
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Type
11. Global Novel Drug Delivery Systems Market
Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Humans
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.1.3.
Market
Forecast, 2021 - 2029
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Animals
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.2.3.
Market
Forecast, 2021 - 2029
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By Application
12. Global Novel Drug Delivery Systems Market
Analysis and Forecasts, 2021 – 2029
12.1. Overview
12.2. Global Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By End-Users
12.2.1. Research Institutions
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
12.2.1.3.
Market
Forecast, 2021 - 2029
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market Estimation, 2015 - 2020
12.2.1.5.1.2. Market Forecast, 2021 - 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2020
12.2.1.5.2.2. Market Forecast, 2021 - 2029
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2020
12.2.1.5.3.2. Market Forecast, 2021 - 2029
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2020
12.2.1.5.4.2. Market Forecast, 2021 - 2029
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market Estimation, 2015 - 2020
12.2.1.5.5.2. Market Forecast, 2021 - 2029
12.2.2. Healthcare Facilities
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
12.2.2.3.
Market
Forecast, 2021 - 2029
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market Estimation, 2015 - 2020
12.2.2.5.1.2. Market Forecast, 2021 - 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2020
12.2.2.5.2.2. Market Forecast, 2021 - 2029
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2020
12.2.2.5.3.2. Market Forecast, 2021 - 2029
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2020
12.2.2.5.4.2. Market Forecast, 2021 - 2029
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market Estimation, 2015 - 2020
12.2.2.5.5.2. Market Forecast, 2021 - 2029
12.2.3. Speciality Clinics
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
12.2.3.3.
Market
Forecast, 2021 - 2029
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1. Market Estimation, 2015 - 2020
12.2.3.5.1.2. Market Forecast, 2021 - 2029
12.2.3.5.2. Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2020
12.2.3.5.2.2. Market Forecast, 2021 - 2029
12.2.3.5.3. Asia Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2020
12.2.3.5.3.2. Market Forecast, 2021 - 2029
12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2020
12.2.3.5.4.2. Market Forecast, 2021 - 2029
12.2.3.5.5. Latin America
12.2.3.5.5.1. Market Estimation, 2015 - 2020
12.2.3.5.5.2. Market Forecast, 2021 - 2029
12.2.4. Pharmaceutical Companies
12.2.4.1.
Definition
12.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
12.2.4.3.
Market
Forecast, 2021 - 2029
12.2.4.4.
Compound
Annual Growth Rate (CAGR)
12.2.4.5.
Regional
Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1. Market Estimation, 2015 - 2020
12.2.4.5.1.2. Market Forecast, 2021 - 2029
12.2.4.5.2. Europe
12.2.4.5.2.1. Market Estimation, 2015 - 2020
12.2.4.5.2.2. Market Forecast, 2021 - 2029
12.2.4.5.3. Asia Pacific
12.2.4.5.3.1. Market Estimation, 2015 - 2020
12.2.4.5.3.2. Market Forecast, 2021 - 2029
12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market Estimation, 2015 - 2020
12.2.4.5.4.2. Market Forecast, 2021 - 2029
12.2.4.5.5. Latin America
12.2.4.5.5.1. Market Estimation, 2015 - 2020
12.2.4.5.5.2. Market Forecast, 2021 - 2029
12.2.5. Geriatric Care Centres
12.2.5.1.
Definition
12.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
12.2.5.3.
Market
Forecast, 2021 - 2029
12.2.5.4.
Compound
Annual Growth Rate (CAGR)
12.2.5.5.
Regional
Bifurcation
12.2.5.5.1. North America
12.2.5.5.1.1. Market Estimation, 2015 - 2020
12.2.5.5.1.2. Market Forecast, 2021 - 2029
12.2.5.5.2. Europe
12.2.5.5.2.1. Market Estimation, 2015 - 2020
12.2.5.5.2.2. Market Forecast, 2021 - 2029
12.2.5.5.3. Asia Pacific
12.2.5.5.3.1. Market Estimation, 2015 - 2020
12.2.5.5.3.2. Market Forecast, 2021 - 2029
12.2.5.5.4. Middle East and Africa
12.2.5.5.4.1. Market Estimation, 2015 - 2020
12.2.5.5.4.2. Market Forecast, 2021 - 2029
12.2.5.5.5. Latin America
12.2.5.5.5.1. Market Estimation, 2015 - 2020
12.2.5.5.5.2. Market Forecast, 2021 - 2029
12.2.6. Others
12.2.6.1.
Definition
12.2.6.2.
Market Estimation
and Penetration, 2015 - 2020
12.2.6.3.
Market
Forecast, 2021 - 2029
12.2.6.4.
Compound
Annual Growth Rate (CAGR)
12.2.6.5.
Regional
Bifurcation
12.2.6.5.1. North America
12.2.6.5.1.1. Market Estimation, 2015 - 2020
12.2.6.5.1.2. Market Forecast, 2021 - 2029
12.2.6.5.2. Europe
12.2.6.5.2.1. Market Estimation, 2015 - 2020
12.2.6.5.2.2. Market Forecast, 2021 - 2029
12.2.6.5.3. Asia Pacific
12.2.6.5.3.1. Market Estimation, 2015 - 2020
12.2.6.5.3.2. Market Forecast, 2021 - 2029
12.2.6.5.4. Middle East and Africa
12.2.6.5.4.1. Market Estimation, 2015 - 2020
12.2.6.5.4.2. Market Forecast, 2021 - 2029
12.2.6.5.5. Latin America
12.2.6.5.5.1. Market Estimation, 2015 - 2020
12.2.6.5.5.2. Market Forecast, 2021 - 2029
12.3. Key Segment for Channeling Investments
12.3.1. By End-Users
13. North America Novel Drug Delivery Systems
Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn)
13.2. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Carrier Type
13.2.1. Liposomes
13.2.2. Phytosomes
13.2.3. Nanoparticles
13.2.4. Niosomes
13.2.5. Proniosomes
13.2.6. Microspheres
13.2.7. Emulsions
13.2.8. Ethosomes
13.2.9. Transfereosomes
13.2.10. Others
13.3. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.3.1. Oral
13.3.2. Inhalation
13.3.3. Skin Absorption
13.3.4. Intravenous
13.3.5. Pulmonary Route
13.3.6. Others
13.4. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Type
13.4.1. Targeted Drug Delivery
13.4.2. Controlled Drug Delivery
13.4.3. Modulated Drug Delivery
13.5. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1. Humans
13.5.2. Animals
13.6. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.1. Research Institutions
13.6.2. Healthcare Facilities
13.6.3. Speciality Clinics
13.6.4. Pharmaceutical Companies
13.6.5. Geriatric Care Centres
13.6.6. Others
13.7. North America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
13.7.1.1.1. Liposomes
13.7.1.1.2. Phytosomes
13.7.1.1.3. Nanoparticles
13.7.1.1.4. Niosomes
13.7.1.1.5. Proniosomes
13.7.1.1.6. Microspheres
13.7.1.1.7. Emulsions
13.7.1.1.8. Ethosomes
13.7.1.1.9. Transfereosomes
13.7.1.1.10. Others
13.7.1.2.
U.S
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.1.2.1. Oral
13.7.1.2.2. Inhalation
13.7.1.2.3. Skin Absorption
13.7.1.2.4. Intravenous
13.7.1.2.5. Pulmonary Route
13.7.1.2.6. Others
13.7.1.3.
U.S
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
13.7.1.3.1. Targeted Drug Delivery
13.7.1.3.2. Controlled Drug Delivery
13.7.1.3.3. Modulated Drug Delivery
13.7.1.4.
U.S
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Application
13.7.1.4.1. Humans
13.7.1.4.2. Animals
13.7.1.5.
U.S
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
13.7.1.5.1. Research Institutions
13.7.1.5.2. Healthcare Facilities
13.7.1.5.3. Speciality Clinics
13.7.1.5.4. Pharmaceutical Companies
13.7.1.5.5. Geriatric Care Centres
13.7.1.5.6. Others
13.7.2. Canada
13.7.2.1.
Canada
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
13.7.2.1.1. Liposomes
13.7.2.1.2. Phytosomes
13.7.2.1.3. Nanoparticles
13.7.2.1.4. Niosomes
13.7.2.1.5. Proniosomes
13.7.2.1.6. Microspheres
13.7.2.1.7. Emulsions
13.7.2.1.8. Ethosomes
13.7.2.1.9. Transfereosomes
13.7.2.1.10. Others
13.7.2.2.
Canada
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.2.2.1. Oral
13.7.2.2.2. Inhalation
13.7.2.2.3. Skin Absorption
13.7.2.2.4. Intravenous
13.7.2.2.5. Pulmonary Route
13.7.2.2.6. Others
13.7.2.3.
Canada
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
13.7.2.3.1. Targeted Drug Delivery
13.7.2.3.2. Controlled Drug Delivery
13.7.2.3.3. Modulated Drug Delivery
13.7.2.4.
Canada Novel
Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Application
13.7.2.4.1. Humans
13.7.2.4.2. Animals
13.7.2.5.
Canada
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
13.7.2.5.1. Research Institutions
13.7.2.5.2. Healthcare Facilities
13.7.2.5.3. Speciality Clinics
13.7.2.5.4. Pharmaceutical Companies
13.7.2.5.5. Geriatric Care Centres
13.7.2.5.6. Others
13.7.3. Mexico
13.7.3.1.
Mexico
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
13.7.3.1.1. Liposomes
13.7.3.1.2. Phytosomes
13.7.3.1.3. Nanoparticles
13.7.3.1.4. Niosomes
13.7.3.1.5. Proniosomes
13.7.3.1.6. Microspheres
13.7.3.1.7. Emulsions
13.7.3.1.8. Ethosomes
13.7.3.1.9. Transfereosomes
13.7.3.1.10. Others
13.7.3.2.
Mexico
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.3.2.1. Oral
13.7.3.2.2. Inhalation
13.7.3.2.3. Skin Absorption
13.7.3.2.4. Intravenous
13.7.3.2.5. Pulmonary Route
13.7.3.2.6. Others
13.7.3.3.
Mexico
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
13.7.3.3.1. Targeted Drug Delivery
13.7.3.3.2. Controlled Drug Delivery
13.7.3.3.3. Modulated Drug Delivery
13.7.3.4.
Mexico
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
13.7.3.4.1. Humans
13.7.3.4.2. Animals
13.7.3.5.
Mexico
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
13.7.3.5.1. Research Institutions
13.7.3.5.2. Healthcare Facilities
13.7.3.5.3. Speciality Clinics
13.7.3.5.4. Pharmaceutical Companies
13.7.3.5.5. Geriatric Care Centres
13.7.3.5.6. Others
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Carrier Type
13.7.4.1.1. Liposomes
13.7.4.1.2. Phytosomes
13.7.4.1.3. Nanoparticles
13.7.4.1.4. Niosomes
13.7.4.1.5. Proniosomes
13.7.4.1.6. Microspheres
13.7.4.1.7. Emulsions
13.7.4.1.8. Ethosomes
13.7.4.1.9. Transfereosomes
13.7.4.1.10. Others
13.7.4.2.
Rest of
North America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.4.2.1. Oral
13.7.4.2.2. Inhalation
13.7.4.2.3. Skin Absorption
13.7.4.2.4. Intravenous
13.7.4.2.5. Pulmonary Route
13.7.4.2.6. Others
13.7.4.3.
Rest of
North America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.4.3.1. Targeted Drug Delivery
13.7.4.3.2. Controlled Drug Delivery
13.7.4.3.3. Modulated Drug Delivery
13.7.4.4.
Rest of
North America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.4.4.1. Humans
13.7.4.4.2. Animals
13.7.4.5.
Rest of
North America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.7.4.5.1. Research Institutions
13.7.4.5.2. Healthcare Facilities
13.7.4.5.3. Speciality Clinics
13.7.4.5.4. Pharmaceutical Companies
13.7.4.5.5. Geriatric Care Centres
13.7.4.5.6. Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Carrier Type
13.8.3. By Route of Administration
13.8.4. By Type
13.8.5. By Application
13.8.6. By End-Users
14. Europe Novel Drug Delivery Systems Market
Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn)
14.2. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Carrier Type
14.2.1. Liposomes
14.2.2. Phytosomes
14.2.3. Nanoparticles
14.2.4. Niosomes
14.2.5. Proniosomes
14.2.6. Microspheres
14.2.7. Emulsions
14.2.8. Ethosomes
14.2.9. Transfereosomes
14.2.10. Others
14.3. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.3.1. Oral
14.3.2. Inhalation
14.3.3. Skin Absorption
14.3.4. Intravenous
14.3.5. Pulmonary Route
14.3.6. Others
14.4. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Type
14.4.1. Targeted Drug Delivery
14.4.2. Controlled Drug Delivery
14.4.3. Modulated Drug Delivery
14.5. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.1. Humans
14.5.2. Animals
14.6. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By End-Users
14.6.1. Research Institutions
14.6.2. Healthcare Facilities
14.6.3. Speciality Clinics
14.6.4. Pharmaceutical Companies
14.6.5. Geriatric Care Centres
14.6.6. Others
14.7. Europe Novel Drug Delivery Systems Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
14.7.1.1.1. Liposomes
14.7.1.1.2. Phytosomes
14.7.1.1.3. Nanoparticles
14.7.1.1.4. Niosomes
14.7.1.1.5. Proniosomes
14.7.1.1.6. Microspheres
14.7.1.1.7. Emulsions
14.7.1.1.8. Ethosomes
14.7.1.1.9. Transfereosomes
14.7.1.1.10. Others
14.7.1.2.
France
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.1.2.1. Oral
14.7.1.2.2. Inhalation
14.7.1.2.3. Skin Absorption
14.7.1.2.4. Intravenous
14.7.1.2.5. Pulmonary Route
14.7.1.2.6. Others
14.7.1.3.
France
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
14.7.1.3.1. Targeted Drug Delivery
14.7.1.3.2. Controlled Drug Delivery
14.7.1.3.3. Modulated Drug Delivery
14.7.1.4.
France
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.1.4.1. Humans
14.7.1.4.2. Animals
14.7.1.5.
France
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
14.7.1.5.1. Research Institutions
14.7.1.5.2. Healthcare Facilities
14.7.1.5.3. Speciality Clinics
14.7.1.5.4. Pharmaceutical Companies
14.7.1.5.5. Geriatric Care Centres
14.7.1.5.6. Others
14.7.2. The UK
14.7.2.1.
The UK
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
14.7.2.1.1. Liposomes
14.7.2.1.2. Phytosomes
14.7.2.1.3. Nanoparticles
14.7.2.1.4. Niosomes
14.7.2.1.5. Proniosomes
14.7.2.1.6. Microspheres
14.7.2.1.7. Emulsions
14.7.2.1.8. Ethosomes
14.7.2.1.9. Transfereosomes
14.7.2.1.10. Others
14.7.2.2.
The UK
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.2.2.1. Oral
14.7.2.2.2. Inhalation
14.7.2.2.3. Skin Absorption
14.7.2.2.4. Intravenous
14.7.2.2.5. Pulmonary Route
14.7.2.2.6. Others
14.7.2.3.
The UK
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
14.7.2.3.1. Targeted Drug Delivery
14.7.2.3.2. Controlled Drug Delivery
14.7.2.3.3. Modulated Drug Delivery
14.7.2.4.
The UK
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.2.4.1. Humans
14.7.2.4.2. Animals
14.7.2.5.
The UK
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
14.7.2.5.1. Research Institutions
14.7.2.5.2. Healthcare Facilities
14.7.2.5.3. Speciality Clinics
14.7.2.5.4. Pharmaceutical Companies
14.7.2.5.5. Geriatric Care Centres
14.7.2.5.6. Others
14.7.3. Spain
14.7.3.1.
Spain
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
14.7.3.1.1. Liposomes
14.7.3.1.2. Phytosomes
14.7.3.1.3. Nanoparticles
14.7.3.1.4. Niosomes
14.7.3.1.5. Proniosomes
14.7.3.1.6. Microspheres
14.7.3.1.7. Emulsions
14.7.3.1.8. Ethosomes
14.7.3.1.9. Transfereosomes
14.7.3.1.10. Others
14.7.3.2.
Spain
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.3.2.1. Oral
14.7.3.2.2. Inhalation
14.7.3.2.3. Skin Absorption
14.7.3.2.4. Intravenous
14.7.3.2.5. Pulmonary Route
14.7.3.2.6. Others
14.7.3.3.
Spain
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
14.7.3.3.1. Targeted Drug Delivery
14.7.3.3.2. Controlled Drug Delivery
14.7.3.3.3. Modulated Drug Delivery
14.7.3.4.
Spain
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.3.4.1. Humans
14.7.3.4.2. Animals
14.7.3.5.
Spain
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
14.7.3.5.1. Research Institutions
14.7.3.5.2. Healthcare Facilities
14.7.3.5.3. Speciality Clinics
14.7.3.5.4. Pharmaceutical Companies
14.7.3.5.5. Geriatric Care Centres
14.7.3.5.6. Others
14.7.4. Germany
14.7.4.1.
Germany
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
14.7.4.1.1. Liposomes
14.7.4.1.2. Phytosomes
14.7.4.1.3. Nanoparticles
14.7.4.1.4. Niosomes
14.7.4.1.5. Proniosomes
14.7.4.1.6. Microspheres
14.7.4.1.7. Emulsions
14.7.4.1.8. Ethosomes
14.7.4.1.9. Transfereosomes
14.7.4.1.10. Others
14.7.4.2.
Germany
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.4.2.1. Oral
14.7.4.2.2. Inhalation
14.7.4.2.3. Skin Absorption
14.7.4.2.4. Intravenous
14.7.4.2.5. Pulmonary Route
14.7.4.2.6. Others
14.7.4.3.
Germany
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
14.7.4.3.1. Targeted Drug Delivery
14.7.4.3.2. Controlled Drug Delivery
14.7.4.3.3. Modulated Drug Delivery
14.7.4.4.
Germany
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.4.4.1. Humans
14.7.4.4.2. Animals
14.7.4.5.
Germany
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
14.7.4.5.1. Research Institutions
14.7.4.5.2. Healthcare Facilities
14.7.4.5.3. Speciality Clinics
14.7.4.5.4. Pharmaceutical Companies
14.7.4.5.5. Geriatric Care Centres
14.7.4.5.6. Others
14.7.5. Italy
14.7.5.1.
Italy
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
14.7.5.1.1. Liposomes
14.7.5.1.2. Phytosomes
14.7.5.1.3. Nanoparticles
14.7.5.1.4. Niosomes
14.7.5.1.5. Proniosomes
14.7.5.1.6. Microspheres
14.7.5.1.7. Emulsions
14.7.5.1.8. Ethosomes
14.7.5.1.9. Transfereosomes
14.7.5.1.10. Others
14.7.5.2.
Italy
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.5.2.1. Oral
14.7.5.2.2. Inhalation
14.7.5.2.3. Skin Absorption
14.7.5.2.4. Intravenous
14.7.5.2.5. Pulmonary Route
14.7.5.2.6. Others
14.7.5.3.
Italy
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
14.7.5.3.1. Targeted Drug Delivery
14.7.5.3.2. Controlled Drug Delivery
14.7.5.3.3. Modulated Drug Delivery
14.7.5.4.
Italy
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.5.4.1. Humans
14.7.5.4.2. Animals
14.7.5.5.
Italy
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
14.7.5.5.1. Research Institutions
14.7.5.5.2. Healthcare Facilities
14.7.5.5.3. Speciality Clinics
14.7.5.5.4. Pharmaceutical Companies
14.7.5.5.5. Geriatric Care Centres
14.7.5.5.6. Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
14.7.6.1.1. Liposomes
14.7.6.1.2. Phytosomes
14.7.6.1.3. Nanoparticles
14.7.6.1.4. Niosomes
14.7.6.1.5. Proniosomes
14.7.6.1.6. Microspheres
14.7.6.1.7. Emulsions
14.7.6.1.8. Ethosomes
14.7.6.1.9. Transfereosomes
14.7.6.1.10. Others
14.7.6.2.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.6.2.1. Oral
14.7.6.2.2. Inhalation
14.7.6.2.3. Skin Absorption
14.7.6.2.4. Intravenous
14.7.6.2.5. Pulmonary Route
14.7.6.2.6. Others
14.7.6.3.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.6.3.1. Targeted Drug Delivery
14.7.6.3.2. Controlled Drug Delivery
14.7.6.3.3. Modulated Drug Delivery
14.7.6.4.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.6.4.1. Humans
14.7.6.4.2. Animals
14.7.6.5.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.7.6.5.1. Research Institutions
14.7.6.5.2. Healthcare Facilities
14.7.6.5.3. Speciality Clinics
14.7.6.5.4. Pharmaceutical Companies
14.7.6.5.5. Geriatric Care Centres
14.7.6.5.6. Others
14.7.6.6.
Nordic
Countries Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
14.7.7.1.1. Liposomes
14.7.7.1.2. Phytosomes
14.7.7.1.3. Nanoparticles
14.7.7.1.4. Niosomes
14.7.7.1.5. Proniosomes
14.7.7.1.6. Microspheres
14.7.7.1.7. Emulsions
14.7.7.1.8. Ethosomes
14.7.7.1.9. Transfereosomes
14.7.7.1.10. Others
14.7.7.2.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.7.2.1. Oral
14.7.7.2.2. Inhalation
14.7.7.2.3. Skin Absorption
14.7.7.2.4. Intravenous
14.7.7.2.5. Pulmonary Route
14.7.7.2.6. Others
14.7.7.3.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.7.3.1. Targeted Drug Delivery
14.7.7.3.2. Controlled Drug Delivery
14.7.7.3.3. Modulated Drug Delivery
14.7.7.4.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.7.4.1. Humans
14.7.7.4.2. Animals
14.7.7.5.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.7.7.5.1. Research Institutions
14.7.7.5.2. Healthcare Facilities
14.7.7.5.3. Speciality Clinics
14.7.7.5.4. Pharmaceutical Companies
14.7.7.5.5. Geriatric Care Centres
14.7.7.5.6. Others
14.7.7.6.
Benelux
Union Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
14.7.8.1.1. Liposomes
14.7.8.1.2. Phytosomes
14.7.8.1.3. Nanoparticles
14.7.8.1.4. Niosomes
14.7.8.1.5. Proniosomes
14.7.8.1.6. Microspheres
14.7.8.1.7. Emulsions
14.7.8.1.8. Ethosomes
14.7.8.1.9. Transfereosomes
14.7.8.1.10. Others
14.7.8.2.
Rest of
Europe Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.8.2.1. Oral
14.7.8.2.2. Inhalation
14.7.8.2.3. Skin Absorption
14.7.8.2.4. Intravenous
14.7.8.2.5. Pulmonary Route
14.7.8.2.6. Others
14.7.8.3.
Rest of
Europe Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.8.3.1. Targeted Drug Delivery
14.7.8.3.2. Controlled Drug Delivery
14.7.8.3.3. Modulated Drug Delivery
14.7.8.4.
Rest of
Europe Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.8.4.1. Humans
14.7.8.4.2. Animals
14.7.8.5.
Rest of
Europe Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.7.8.5.1. Research Institutions
14.7.8.5.2. Healthcare Facilities
14.7.8.5.3. Speciality Clinics
14.7.8.5.4. Pharmaceutical Companies
14.7.8.5.5. Geriatric Care Centres
14.7.8.5.6. Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Carrier Type
14.8.3. By Route of Administration
14.8.4. By Type
14.8.5. By Application
14.8.6. By End-Users
15. Asia Pacific Novel Drug Delivery Systems
Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn)
15.2. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Carrier Type
15.2.1. Liposomes
15.2.2. Phytosomes
15.2.3. Nanoparticles
15.2.4. Niosomes
15.2.5. Proniosomes
15.2.6. Microspheres
15.2.7. Emulsions
15.2.8. Ethosomes
15.2.9. Transfereosomes
15.2.10. Others
15.3. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Oral
15.3.2. Inhalation
15.3.3. Skin Absorption
15.3.4. Intravenous
15.3.5. Pulmonary Route
15.3.6. Others
15.4. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Type
15.4.1. Targeted Drug Delivery
15.4.2. Controlled Drug Delivery
15.4.3. Modulated Drug Delivery
15.5. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1. Humans
15.5.2. Animals
15.6. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.1. Research Institutions
15.6.2. Healthcare Facilities
15.6.3. Speciality Clinics
15.6.4. Pharmaceutical Companies
15.6.5. Geriatric Care Centres
15.6.6. Others
15.7. Asia Pacific Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
15.7.1.1.1. Liposomes
15.7.1.1.2. Phytosomes
15.7.1.1.3. Nanoparticles
15.7.1.1.4. Niosomes
15.7.1.1.5. Proniosomes
15.7.1.1.6. Microspheres
15.7.1.1.7. Emulsions
15.7.1.1.8. Ethosomes
15.7.1.1.9. Transfereosomes
15.7.1.1.10. Others
15.7.1.2.
China
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.1.2.1. Oral
15.7.1.2.2. Inhalation
15.7.1.2.3. Skin Absorption
15.7.1.2.4. Intravenous
15.7.1.2.5. Pulmonary Route
15.7.1.2.6. Others
15.7.1.3.
China
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
15.7.1.3.1. Targeted Drug Delivery
15.7.1.3.2. Controlled Drug Delivery
15.7.1.3.3. Modulated Drug Delivery
15.7.1.4.
China
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.1.4.1. Humans
15.7.1.4.2. Animals
15.7.1.5.
China
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
15.7.1.5.1. Research Institutions
15.7.1.5.2. Healthcare Facilities
15.7.1.5.3. Speciality Clinics
15.7.1.5.4. Pharmaceutical Companies
15.7.1.5.5. Geriatric Care Centres
15.7.1.5.6. Others
15.7.2. Japan
15.7.2.1.
Japan
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
15.7.2.1.1. Liposomes
15.7.2.1.2. Phytosomes
15.7.2.1.3. Nanoparticles
15.7.2.1.4. Niosomes
15.7.2.1.5. Proniosomes
15.7.2.1.6. Microspheres
15.7.2.1.7. Emulsions
15.7.2.1.8. Ethosomes
15.7.2.1.9. Transfereosomes
15.7.2.1.10. Others
15.7.2.2.
Japan
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.2.2.1. Oral
15.7.2.2.2. Inhalation
15.7.2.2.3. Skin Absorption
15.7.2.2.4. Intravenous
15.7.2.2.5. Pulmonary Route
15.7.2.2.6. Others
15.7.2.3.
Japan
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
15.7.2.3.1. Targeted Drug Delivery
15.7.2.3.2. Controlled Drug Delivery
15.7.2.3.3. Modulated Drug Delivery
15.7.2.4.
Japan
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.2.4.1. Humans
15.7.2.4.2. Animals
15.7.2.5.
Japan
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
15.7.2.5.1. Research Institutions
15.7.2.5.2. Healthcare Facilities
15.7.2.5.3. Speciality Clinics
15.7.2.5.4. Pharmaceutical Companies
15.7.2.5.5. Geriatric Care Centres
15.7.2.5.6. Others
15.7.3. India
15.7.3.1.
India
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
15.7.3.1.1. Liposomes
15.7.3.1.2. Phytosomes
15.7.3.1.3. Nanoparticles
15.7.3.1.4. Niosomes
15.7.3.1.5. Proniosomes
15.7.3.1.6. Microspheres
15.7.3.1.7. Emulsions
15.7.3.1.8. Ethosomes
15.7.3.1.9. Transfereosomes
15.7.3.1.10. Others
15.7.3.2.
India
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.3.2.1. Oral
15.7.3.2.2. Inhalation
15.7.3.2.3. Skin Absorption
15.7.3.2.4. Intravenous
15.7.3.2.5. Pulmonary Route
15.7.3.2.6. Others
15.7.3.3.
India
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
15.7.3.3.1. Targeted Drug Delivery
15.7.3.3.2. Controlled Drug Delivery
15.7.3.3.3. Modulated Drug Delivery
15.7.3.4.
India
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.3.4.1. Humans
15.7.3.4.2. Animals
15.7.3.5.
India
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
15.7.3.5.1. Research Institutions
15.7.3.5.2. Healthcare Facilities
15.7.3.5.3. Speciality Clinics
15.7.3.5.4. Pharmaceutical Companies
15.7.3.5.5. Geriatric Care Centres
15.7.3.5.6. Others
15.7.4. New Zealand
15.7.4.1.
New
Zealand Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
15.7.4.1.1. Liposomes
15.7.4.1.2. Phytosomes
15.7.4.1.3. Nanoparticles
15.7.4.1.4. Niosomes
15.7.4.1.5. Proniosomes
15.7.4.1.6. Microspheres
15.7.4.1.7. Emulsions
15.7.4.1.8. Ethosomes
15.7.4.1.9. Transfereosomes
15.7.4.1.10. Others
15.7.4.2.
New
Zealand Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.4.2.1. Oral
15.7.4.2.2. Inhalation
15.7.4.2.3. Skin Absorption
15.7.4.2.4. Intravenous
15.7.4.2.5. Pulmonary Route
15.7.4.2.6. Others
15.7.4.3.
New
Zealand Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.4.3.1. Targeted Drug Delivery
15.7.4.3.2. Controlled Drug Delivery
15.7.4.3.3. Modulated Drug Delivery
15.7.4.4.
New
Zealand Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.4.4.1. Humans
15.7.4.4.2. Animals
15.7.4.5.
New Zealand
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
15.7.4.5.1. Research Institutions
15.7.4.5.2. Healthcare Facilities
15.7.4.5.3. Speciality Clinics
15.7.4.5.4. Pharmaceutical Companies
15.7.4.5.5. Geriatric Care Centres
15.7.4.5.6. Others
15.7.5. Australia
15.7.5.1.
Australia
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
15.7.5.1.1. Liposomes
15.7.5.1.2. Phytosomes
15.7.5.1.3. Nanoparticles
15.7.5.1.4. Niosomes
15.7.5.1.5. Proniosomes
15.7.5.1.6. Microspheres
15.7.5.1.7. Emulsions
15.7.5.1.8. Ethosomes
15.7.5.1.9. Transfereosomes
15.7.5.1.10. Others
15.7.5.2.
Australia
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.5.2.1. Oral
15.7.5.2.2. Inhalation
15.7.5.2.3. Skin Absorption
15.7.5.2.4. Intravenous
15.7.5.2.5. Pulmonary Route
15.7.5.2.6. Others
15.7.5.3.
Australia
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
15.7.5.3.1. Targeted Drug Delivery
15.7.5.3.2. Controlled Drug Delivery
15.7.5.3.3. Modulated Drug Delivery
15.7.5.4.
Australia
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.5.4.1. Humans
15.7.5.4.2. Animals
15.7.5.5.
Australia
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
15.7.5.5.1. Research Institutions
15.7.5.5.2. Healthcare Facilities
15.7.5.5.3. Speciality Clinics
15.7.5.5.4. Pharmaceutical Companies
15.7.5.5.5. Geriatric Care Centres
15.7.5.5.6. Others
15.7.6. South Korea
15.7.6.1.
South
Korea Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
15.7.6.1.1. Liposomes
15.7.6.1.2. Phytosomes
15.7.6.1.3. Nanoparticles
15.7.6.1.4. Niosomes
15.7.6.1.5. Proniosomes
15.7.6.1.6. Microspheres
15.7.6.1.7. Emulsions
15.7.6.1.8. Ethosomes
15.7.6.1.9. Transfereosomes
15.7.6.1.10. Others
15.7.6.2.
South
Korea Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.6.2.1. Oral
15.7.6.2.2. Inhalation
15.7.6.2.3. Skin Absorption
15.7.6.2.4. Intravenous
15.7.6.2.5. Pulmonary Route
15.7.6.2.6. Others
15.7.6.3.
South
Korea Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.6.3.1. Targeted Drug Delivery
15.7.6.3.2. Controlled Drug Delivery
15.7.6.3.3. Modulated Drug Delivery
15.7.6.4.
South
Korea Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.6.4.1. Humans
15.7.6.4.2. Animals
15.7.6.5.
South
Korea Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.7.6.5.1. Research Institutions
15.7.6.5.2. Healthcare Facilities
15.7.6.5.3. Speciality Clinics
15.7.6.5.4. Pharmaceutical Companies
15.7.6.5.5. Geriatric Care Centres
15.7.6.5.6. Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
15.7.7.1.1. Liposomes
15.7.7.1.2. Phytosomes
15.7.7.1.3. Nanoparticles
15.7.7.1.4. Niosomes
15.7.7.1.5. Proniosomes
15.7.7.1.6. Microspheres
15.7.7.1.7. Emulsions
15.7.7.1.8. Ethosomes
15.7.7.1.9. Transfereosomes
15.7.7.1.10. Others
15.7.7.2.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.7.2.1. Oral
15.7.7.2.2. Inhalation
15.7.7.2.3. Skin Absorption
15.7.7.2.4. Intravenous
15.7.7.2.5. Pulmonary Route
15.7.7.2.6. Others
15.7.7.3.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
15.7.7.3.1. Targeted Drug Delivery
15.7.7.3.2. Controlled Drug Delivery
15.7.7.3.3. Modulated Drug Delivery
15.7.7.4.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.7.4.1. Humans
15.7.7.4.2. Animals
15.7.7.5.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.7.7.5.1. Research Institutions
15.7.7.5.2. Healthcare Facilities
15.7.7.5.3. Speciality Clinics
15.7.7.5.4. Pharmaceutical Companies
15.7.7.5.5. Geriatric Care Centres
15.7.7.5.6. Others
15.7.7.6.
Southeast
Asia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By Carrier Type
15.7.8.1.1. Liposomes
15.7.8.1.2. Phytosomes
15.7.8.1.3. Nanoparticles
15.7.8.1.4. Niosomes
15.7.8.1.5. Proniosomes
15.7.8.1.6. Microspheres
15.7.8.1.7. Emulsions
15.7.8.1.8. Ethosomes
15.7.8.1.9. Transfereosomes
15.7.8.1.10. Others
15.7.8.2.
Rest of
Asia Pacific Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.8.2.1. Oral
15.7.8.2.2. Inhalation
15.7.8.2.3. Skin Absorption
15.7.8.2.4. Intravenous
15.7.8.2.5. Pulmonary Route
15.7.8.2.6. Others
15.7.8.3.
Rest of
Asia Pacific Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By Type
15.7.8.3.1. Targeted Drug Delivery
15.7.8.3.2. Controlled Drug Delivery
15.7.8.3.3. Modulated Drug Delivery
15.7.8.4.
Rest of
Asia Pacific Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By Application
15.7.8.4.1. Humans
15.7.8.4.2. Animals
15.7.8.5.
Rest of
Asia Pacific Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By End-Users
15.7.8.5.1. Research Institutions
15.7.8.5.2. Healthcare Facilities
15.7.8.5.3. Speciality Clinics
15.7.8.5.4. Pharmaceutical Companies
15.7.8.5.5. Geriatric Care Centres
15.7.8.5.6. Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Carrier Type
15.8.3. By Route of Administration
15.8.4. By Type
15.8.5. By Application
15.8.6. By End-Users
16. Middle East and Africa Novel Drug Delivery
Systems Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn)
16.2. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By Carrier Type
16.2.1. Liposomes
16.2.2. Phytosomes
16.2.3. Nanoparticles
16.2.4. Niosomes
16.2.5. Proniosomes
16.2.6. Microspheres
16.2.7. Emulsions
16.2.8. Ethosomes
16.2.9. Transfereosomes
16.2.10. Others
16.3. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.3.1. Oral
16.3.2. Inhalation
16.3.3. Skin Absorption
16.3.4. Intravenous
16.3.5. Pulmonary Route
16.3.6. Others
16.4. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By Type
16.4.1. Targeted Drug Delivery
16.4.2. Controlled Drug Delivery
16.4.3. Modulated Drug Delivery
16.5. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Humans
16.5.2. Animals
16.6. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
16.6.1. Research Institutions
16.6.2. Healthcare Facilities
16.6.3. Speciality Clinics
16.6.4. Pharmaceutical Companies
16.6.5. Geriatric Care Centres
16.6.6. Others
16.7. Middle East and Africa Novel Drug Delivery
Systems Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
16.7.1.1.1. Liposomes
16.7.1.1.2. Phytosomes
16.7.1.1.3. Nanoparticles
16.7.1.1.4. Niosomes
16.7.1.1.5. Proniosomes
16.7.1.1.6. Microspheres
16.7.1.1.7. Emulsions
16.7.1.1.8. Ethosomes
16.7.1.1.9. Transfereosomes
16.7.1.1.10. Others
16.7.1.2.
Saudi
Arabia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.1.2.1. Oral
16.7.1.2.2. Inhalation
16.7.1.2.3. Skin Absorption
16.7.1.2.4. Intravenous
16.7.1.2.5. Pulmonary Route
16.7.1.2.6. Others
16.7.1.3.
Saudi
Arabia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
16.7.1.3.1. Targeted Drug Delivery
16.7.1.3.2. Controlled Drug Delivery
16.7.1.3.3. Modulated Drug Delivery
16.7.1.4.
Saudi
Arabia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.1.4.1. Humans
16.7.1.4.2. Animals
16.7.1.5.
Saudi
Arabia Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.7.1.5.1. Research Institutions
16.7.1.5.2. Healthcare Facilities
16.7.1.5.3. Speciality Clinics
16.7.1.5.4. Pharmaceutical Companies
16.7.1.5.5. Geriatric Care Centres
16.7.1.5.6. Others
16.7.2. UAE
16.7.2.1.
UAE
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
16.7.2.1.1. Liposomes
16.7.2.1.2. Phytosomes
16.7.2.1.3. Nanoparticles
16.7.2.1.4. Niosomes
16.7.2.1.5. Proniosomes
16.7.2.1.6. Microspheres
16.7.2.1.7. Emulsions
16.7.2.1.8. Ethosomes
16.7.2.1.9. Transfereosomes
16.7.2.1.10. Others
16.7.2.2.
UAE
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.2.2.1. Oral
16.7.2.2.2. Inhalation
16.7.2.2.3. Skin Absorption
16.7.2.2.4. Intravenous
16.7.2.2.5. Pulmonary Route
16.7.2.2.6. Others
16.7.2.3.
UAE
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
16.7.2.3.1. Targeted Drug Delivery
16.7.2.3.2. Controlled Drug Delivery
16.7.2.3.3. Modulated Drug Delivery
16.7.2.4.
UAE
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.2.4.1. Humans
16.7.2.4.2. Animals
16.7.2.5.
UAE
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
16.7.2.5.1. Research Institutions
16.7.2.5.2. Healthcare Facilities
16.7.2.5.3. Speciality Clinics
16.7.2.5.4. Pharmaceutical Companies
16.7.2.5.5. Geriatric Care Centres
16.7.2.5.6. Others
16.7.3. Egypt
16.7.3.1.
Egypt
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
16.7.3.1.1. Liposomes
16.7.3.1.2. Phytosomes
16.7.3.1.3. Nanoparticles
16.7.3.1.4. Niosomes
16.7.3.1.5. Proniosomes
16.7.3.1.6. Microspheres
16.7.3.1.7. Emulsions
16.7.3.1.8. Ethosomes
16.7.3.1.9. Transfereosomes
16.7.3.1.10. Others
16.7.3.2.
Egypt Novel
Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.3.2.1. Oral
16.7.3.2.2. Inhalation
16.7.3.2.3. Skin Absorption
16.7.3.2.4. Intravenous
16.7.3.2.5. Pulmonary Route
16.7.3.2.6. Others
16.7.3.3.
Egypt
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
16.7.3.3.1. Targeted Drug Delivery
16.7.3.3.2. Controlled Drug Delivery
16.7.3.3.3. Modulated Drug Delivery
16.7.3.4.
Egypt
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.3.4.1. Humans
16.7.3.4.2. Animals
16.7.3.5.
Egypt
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
16.7.3.5.1. Research Institutions
16.7.3.5.2. Healthcare Facilities
16.7.3.5.3. Speciality Clinics
16.7.3.5.4. Pharmaceutical Companies
16.7.3.5.5. Geriatric Care Centres
16.7.3.5.6. Others
16.7.4. Kuwait
16.7.4.1.
Kuwait
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
16.7.4.1.1. Liposomes
16.7.4.1.2. Phytosomes
16.7.4.1.3. Nanoparticles
16.7.4.1.4. Niosomes
16.7.4.1.5. Proniosomes
16.7.4.1.6. Microspheres
16.7.4.1.7. Emulsions
16.7.4.1.8. Ethosomes
16.7.4.1.9. Transfereosomes
16.7.4.1.10. Others
16.7.4.2.
Kuwait
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.4.2.1. Oral
16.7.4.2.2. Inhalation
16.7.4.2.3. Skin Absorption
16.7.4.2.4. Intravenous
16.7.4.2.5. Pulmonary Route
16.7.4.2.6. Others
16.7.4.3.
Kuwait
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
16.7.4.3.1. Targeted Drug Delivery
16.7.4.3.2. Controlled Drug Delivery
16.7.4.3.3. Modulated Drug Delivery
16.7.4.4.
Kuwait
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.4.4.1. Humans
16.7.4.4.2. Animals
16.7.4.5.
Kuwait
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
16.7.4.5.1. Research Institutions
16.7.4.5.2. Healthcare Facilities
16.7.4.5.3. Speciality Clinics
16.7.4.5.4. Pharmaceutical Companies
16.7.4.5.5. Geriatric Care Centres
16.7.4.5.6. Others
16.7.5. South Africa
16.7.5.1.
South
Africa Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Carrier Type
16.7.5.1.1. Liposomes
16.7.5.1.2. Phytosomes
16.7.5.1.3. Nanoparticles
16.7.5.1.4. Niosomes
16.7.5.1.5. Proniosomes
16.7.5.1.6. Microspheres
16.7.5.1.7. Emulsions
16.7.5.1.8. Ethosomes
16.7.5.1.9. Transfereosomes
16.7.5.1.10. Others
16.7.5.2.
South
Africa Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.5.2.1. Oral
16.7.5.2.2. Inhalation
16.7.5.2.3. Skin Absorption
16.7.5.2.4. Intravenous
16.7.5.2.5. Pulmonary Route
16.7.5.2.6. Others
16.7.5.3.
South
Africa Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Type
16.7.5.3.1. Targeted Drug Delivery
16.7.5.3.2. Controlled Drug Delivery
16.7.5.3.3. Modulated Drug Delivery
16.7.5.4.
South
Africa Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.5.4.1. Humans
16.7.5.4.2. Animals
16.7.5.5.
South
Africa Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.7.5.5.1. Research Institutions
16.7.5.5.2. Healthcare Facilities
16.7.5.5.3. Speciality Clinics
16.7.5.5.4. Pharmaceutical Companies
16.7.5.5.5. Geriatric Care Centres
16.7.5.5.6. Others
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Novel Drug Delivery Systems Market Revenue (US$ Mn)
and Forecasts, By Carrier Type
16.7.6.1.1. Liposomes
16.7.6.1.2. Phytosomes
16.7.6.1.3. Nanoparticles
16.7.6.1.4. Niosomes
16.7.6.1.5. Proniosomes
16.7.6.1.6. Microspheres
16.7.6.1.7. Emulsions
16.7.6.1.8. Ethosomes
16.7.6.1.9. Transfereosomes
16.7.6.1.10. Others
16.7.6.2.
Rest of
Middle East & Africa Novel Drug Delivery Systems Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.6.2.1. Oral
16.7.6.2.2. Inhalation
16.7.6.2.3. Skin Absorption
16.7.6.2.4. Intravenous
16.7.6.2.5. Pulmonary Route
16.7.6.2.6. Others
16.7.6.3.
Rest of
Middle East & Africa Novel Drug Delivery Systems Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.6.3.1. Targeted Drug Delivery
16.7.6.3.2. Controlled Drug Delivery
16.7.6.3.3. Modulated Drug Delivery
16.7.6.4.
Rest of
Middle East & Africa Novel Drug Delivery Systems Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.6.4.1. Humans
16.7.6.4.2. Animals
16.7.6.5.
Rest of
Middle East & Africa Novel Drug Delivery Systems Market Revenue (US$ Mn)
and Forecasts, By End-Users
16.7.6.5.1. Research Institutions
16.7.6.5.2. Healthcare Facilities
16.7.6.5.3. Speciality Clinics
16.7.6.5.4. Pharmaceutical Companies
16.7.6.5.5. Geriatric Care Centres
16.7.6.5.6. Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Carrier Type
16.8.3. By Route of Administration
16.8.4. By Type
16.8.5. By Application
16.8.6. By End-Users
17. Latin America Novel Drug Delivery Systems
Market Analysis and Forecasts, 2021 - 2029
17.1. Overview
17.1.1. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn)
17.2. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Carrier Type
17.2.1. Liposomes
17.2.2. Phytosomes
17.2.3. Nanoparticles
17.2.4. Niosomes
17.2.5. Proniosomes
17.2.6. Microspheres
17.2.7. Emulsions
17.2.8. Ethosomes
17.2.9. Transfereosomes
17.2.10. Others
17.3. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.3.1. Oral
17.3.2. Inhalation
17.3.3. Skin Absorption
17.3.4. Intravenous
17.3.5. Pulmonary Route
17.3.6. Others
17.4. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Type
17.4.1. Targeted Drug Delivery
17.4.2. Controlled Drug Delivery
17.4.3. Modulated Drug Delivery
17.5. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Application
17.5.1. Humans
17.5.2. Animals
17.6. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By End-Users
17.6.1. Research Institutions
17.6.2. Healthcare Facilities
17.6.3. Speciality Clinics
17.6.4. Pharmaceutical Companies
17.6.5. Geriatric Care Centres
17.6.6. Others
17.7. Latin America Novel Drug Delivery Systems
Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
17.7.1.1.1. Liposomes
17.7.1.1.2. Phytosomes
17.7.1.1.3. Nanoparticles
17.7.1.1.4. Niosomes
17.7.1.1.5. Proniosomes
17.7.1.1.6. Microspheres
17.7.1.1.7. Emulsions
17.7.1.1.8. Ethosomes
17.7.1.1.9. Transfereosomes
17.7.1.1.10. Others
17.7.1.2.
Brazil
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.1.2.1. Oral
17.7.1.2.2. Inhalation
17.7.1.2.3. Skin Absorption
17.7.1.2.4. Intravenous
17.7.1.2.5. Pulmonary Route
17.7.1.2.6. Others
17.7.1.3.
Brazil
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
17.7.1.3.1. Targeted Drug Delivery
17.7.1.3.2. Controlled Drug Delivery
17.7.1.3.3. Modulated Drug Delivery
17.7.1.4.
Brazil
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
17.7.1.4.1. Humans
17.7.1.4.2. Animals
17.7.1.5.
Brazil
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
17.7.1.5.1. Research Institutions
17.7.1.5.2. Healthcare Facilities
17.7.1.5.3. Speciality Clinics
17.7.1.5.4. Pharmaceutical Companies
17.7.1.5.5. Geriatric Care Centres
17.7.1.5.6. Others
17.7.2. Argentina
17.7.2.1.
Argentina
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Carrier
Type
17.7.2.1.1. Liposomes
17.7.2.1.2. Phytosomes
17.7.2.1.3. Nanoparticles
17.7.2.1.4. Niosomes
17.7.2.1.5. Proniosomes
17.7.2.1.6. Microspheres
17.7.2.1.7. Emulsions
17.7.2.1.8. Ethosomes
17.7.2.1.9. Transfereosomes
17.7.2.1.10. Others
17.7.2.2.
Argentina
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.2.2.1. Oral
17.7.2.2.2. Inhalation
17.7.2.2.3. Skin Absorption
17.7.2.2.4. Intravenous
17.7.2.2.5. Pulmonary Route
17.7.2.2.6. Others
17.7.2.3.
Argentina
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By Type
17.7.2.3.1. Targeted Drug Delivery
17.7.2.3.2. Controlled Drug Delivery
17.7.2.3.3. Modulated Drug Delivery
17.7.2.4.
Argentina
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By
Application
17.7.2.4.1. Humans
17.7.2.4.2. Animals
17.7.2.5.
Argentina
Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts, By End-Users
17.7.2.5.1. Research Institutions
17.7.2.5.2. Healthcare Facilities
17.7.2.5.3. Speciality Clinics
17.7.2.5.4. Pharmaceutical Companies
17.7.2.5.5. Geriatric Care Centres
17.7.2.5.6. Others
17.7.3. Rest of Latin America
17.7.3.1.
Rest of
Latin America Novel Drug Delivery Systems Market Revenue (US$ Mn) and Forecasts,
By Carrier Type
17.7.3.1.1. Liposomes
17.7.3.1.2. Phytosomes
17.7.3.1.3. Nanoparticles
17.7.3.1.4. Niosomes
17.7.3.1.5. Proniosomes
17.7.3.1.6. Microspheres
17.7.3.1.7. Emulsions
17.7.3.1.8. Ethosomes
17.7.3.1.9. Transfereosomes
17.7.3.1.10. Others
17.7.3.2.
Rest of
Latin America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.7.3.2.1. Oral
17.7.3.2.2. Inhalation
17.7.3.2.3. Skin Absorption
17.7.3.2.4. Intravenous
17.7.3.2.5. Pulmonary Route
17.7.3.2.6. Others
17.7.3.3.
Rest of
Latin America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.3.3.1. Targeted Drug Delivery
17.7.3.3.2. Controlled Drug Delivery
17.7.3.3.3. Modulated Drug Delivery
17.7.3.4.
Rest of
Latin America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By Application
17.7.3.4.1. Humans
17.7.3.4.2. Animals
17.7.3.5.
Rest of
Latin America Novel Drug Delivery Systems Market Revenue (US$ Mn) and
Forecasts, By End-Users
17.7.3.5.1. Research Institutions
17.7.3.5.2. Healthcare Facilities
17.7.3.5.3. Speciality Clinics
17.7.3.5.4. Pharmaceutical Companies
17.7.3.5.5. Geriatric Care Centres
17.7.3.5.6. Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Carrier Type
17.8.3. By Route of Administration
17.8.4. By Type
17.8.5. By Application
17.8.6. By End-Users
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2020
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Abbott
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Bayer AG
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. Becton, Dickinson and Company
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. BoehringerIngelheim International GmbH
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Enable Injections
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. GlaxoSmithKline plc.
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Insulet Corporation
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Johnson & Johnson Services, Inc.
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. KINDEVA DRUG DELIVERY
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. Koninklijke Philips N.V.
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Lonza Group Ltd.
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. Merck KGaA
19.12.1. Company Details
19.12.2. Company Overview
19.12.3. Product Offerings
19.12.4. Key Developments
19.12.5. Financial Analysis
19.12.6. SWOT Analysis
19.12.7. Business Strategies
19.13. Nemera
19.13.1. Company Details
19.13.2. Company Overview
19.13.3. Product Offerings
19.13.4. Key Developments
19.13.5. Financial Analysis
19.13.6. SWOT Analysis
19.13.7. Business Strategies
19.14. Novartis International AG
19.14.1. Company Details
19.14.2. Company Overview
19.14.3. Product Offerings
19.14.4. Key Developments
19.14.5. Financial Analysis
19.14.6. SWOT Analysis
19.14.7. Business Strategies
19.15. Rapid Dose Therapeutics Inc.
19.15.1. Company Details
19.15.2. Company Overview
19.15.3. Product Offerings
19.15.4. Key Developments
19.15.5. Financial Analysis
19.15.6. SWOT Analysis
19.15.7. Business Strategies
19.16. West Pharmaceutical Services, Inc.
19.16.1. Company Details
19.16.2. Company Overview
19.16.3. Product Offerings
19.16.4. Key Developments
19.16.5. Financial Analysis
19.16.6. SWOT Analysis
19.16.7. Business Strategies
19.17. Other Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
